Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches

•Meta-analysis of NSCLC patients with brain metastases with or without EGFR or ALK mutations.•1st meta-analysis examining patients with brain metastases from NSCLC with confirmed EGFR or ALK mutations.•Examined outcomes following treatment with TKIs, RT, or multimodality approaches.•Patients with EGFR or ALK mutations have improved OS compared to wild-type patients.•No clinical benefit was noted from the addition of TKIs to RT, either WBRT or SRS.